Long-term outcome of imatinib 400 m g compared to imatinib 600 m g or imatinib 400 m g daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial

3 novembre 2021